Literature DB >> 31145034

Interdisciplinary Comparison of PADUA and R.E.N.A.L. Scoring Systems for Prediction of Conversion to Nephrectomy in Patients with Renal Mass Scheduled for Nephron Sparing Surgery.

Lisa Dahlkamp1, Lorine Haeuser1, Guido Winnekendonk2, Christian von Bodman1, Ulrich H Frey3, Robin Epplen1, Rein-Jueri Palisaar1, Peter Bach1, Joachim Noldus1, Marko Brock1, Florian Roghmann1.   

Abstract

PURPOSE: We examined interdisciplinary variability using 2 established preoperative nephrometry scores to predict conversion to nephrectomy in patients with a renal mass who were scheduled for partial nephrectomy.
MATERIALS AND METHODS: A total of 229 consecutive candidates for partial nephrectomy were included in this study at a single institution between January 2013 and May 2017. Patient, tumor and treatment characteristics were assessed. The PADUA (preoperative aspects and dimensions used for an anatomical) score and the R.E.N.A.L. (radius, exophytic/endophytic, nearness of tumor to collecting system or sinus, anterior/posterior, location relative to polar lines) score were independently calculated by board certified radiologists and urological residents using computerized tomography or magnetic resonance imaging. Statistical analyses were done with the κ statistic, ROC curves, and univariable and multivariable binary logistic regression analyses.
RESULTS: Partial nephrectomy was performed in 198 of the 229 cases (86.5%) while 31 (13.5%) were converted to nephrectomy. The prevalent tumor stage was pT1a, noted in 94 of the 229 cases (41.1%), and the predominant histological entity was clear cell carcinoma, found in 128 (55.9%). Radiologist and urologist interdisciplinary comparison of the PADUA and R.E.N.A.L. scores revealed a κ of 0.40 and 0.56, respectively. ROC curve analyses demonstrated a higher AUC predicting conversion to nephrectomy using the PADUA score by the urologist and the radiologist (0.79 and 0.782) compared to that of the R.E.N.A.L. score (0.731 and 0.766, respectively). Using a cutoff of 10 or greater the PADUA score determined by the urologist had 81% sensitivity and 71% specificity, and it was independently associated with conversion to nephrectomy (OR 10.98, p<0.001).
CONCLUSIONS: Our results indicate higher prediction of conversion to nephrectomy when using the PADUA score compared to the R.E.N.A.L. score. Calculation of the PADUA and the R.E.N.A.L. score by physicians without specialized radiological training is feasible and might achieve comparable results to predict conversion to nephrectomy compared to the gold standard provided by board certified radiologists. This information is helpful if nephrometry scores are not regularly included in the radiology report.

Entities:  

Keywords:  diagnostic imaging; kidney neoplasms; nephrectomy; radiologists; urologists

Mesh:

Year:  2019        PMID: 31145034     DOI: 10.1097/JU.0000000000000361

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  The use of nephrometry scoring systems can help urologists predict the risk of conversion to radical nephrectomy in patients scheduled for partial nephrectomy.

Authors:  Vincenzo Ficarra; Marta Rossanese; Gianluca Giannarini; Alessandro Crestani; Alchiede Simonato; Antonino Inferrera
Journal:  Ann Transl Med       Date:  2019-09

2.  A ureteral stricture disease score and classification system: correlation with upper urinary tract reconstructive surgery complexity.

Authors:  Weijie Zhu; Zhenpeng Zhu; Zhihua Li; Xinfei Li; Jianye Zhang; Yangyang Xu; Xiang Wang; Peng Zhang; Bingwei Huang; Chen Huang; Dengxiang Zhang; Hongjian Zhu; Xuesong Li; Jian Lin; Liqun Zhou
Journal:  Transl Androl Urol       Date:  2021-10

3.  Development of a simple nomogram to estimate risk for intraoperative complications before partial nephrectomy based on the Mayo Adhesive Probability score combined with the RENAL nephrometry score.

Authors:  Xiaojun Tan; Dachun Jin; Jian Hu; Weili Zhang; Yu Zhou; Yunxiang Li; Yuanfeng Zhang; Ji Wu
Journal:  Investig Clin Urol       Date:  2021-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.